Evaluating the Efficacy of Bimekizumab Across Different Sensitive Areas in Moderate-to-Severe Psoriasis: 52-week Multicentric Real-Life Experience in Lazio, Italy

Introduction: Psoriasis significantly impacts a patient's quality of life (QoL). Bimekizumab targets IL-17A and IL-17F, offering a broader blockade of the IL-17 pathway compared to other IL-17 inhibitors. Objectives: This study evaluated the clinical efficacy of bimekizumab in bio-naive and bio-experienced patients with moderate-to-severe psoriasis over a 52-week period, with a focus on improvements across different body areas and QoL. Methods: A retrospective analysis of real-world data was conducted on 132 patients from eight medical centers. Efficacy was assessed using PASI scores, at baseline and at weeks 4, 16, 24, and 52, and DLQI scores. Patients were categorized based on prior biologic treatment experience. Results: The mean PASI score decreased for all patients, from 14.41 at baseline to 0.18 at week 52, indicating substantial improvement. Area-specific PASI subscores showed significant reductions: head (3.24 to 0.13), upper limb (8.49 to 0), trunk (8.35 to 0.03), and lower limb (8.61 to 0.12). Complete skin clearance was achieved by week 16 in the majority of patients: 85% achieved complete skin clearance on the head, 90% on upper limbs, and 94% on both trunk and lower limbs. DLQI scores significantly improved, from 13.57 at baseline to 0.86 at week 16, highlighting the early positive impact of bimekizumab in improving QoL. When comparing PASI scores between bio-naive and bio-experienced patients, no significant difference was found. Conclusions: Bimekizumab demonstrates significant efficacy in reducing psoriasis severity across different body areas and improving QoL over a 52-week period. These findings support this robust treatment option for moderate-to-severe psoriasis.